Why Packaging Selection Is Critical for Drug Stability

Improper packaging may lead to accelerated degradation, contamination, or loss of efficacy. Key stability risks influenced by packaging include:

• Exposure to moisture, oxygen, or light
• Migration of substances from the packaging (leachables)
• Adsorption or absorption of active ingredients
• pH or physical changes due to interactions

As per EMA and ICH Q1A guidelines, packaging materials used in stability studies must reflect the final marketed configuration.

Types of Packaging Materials and Their Impact

1. Glass Containers

Glass is chemically inert and offers excellent barrier properties against moisture and gases. However, different types of glass behave differently:

• Type I (Borosilicate): Ideal for parenterals due to low leaching potential
• Type II: Surface-treated soda lime glass—used for non-injectables
• Type III: Suitable for oral solids, not recommended for liquids

Ensure proper hydrolytic resistance testing as per USP .

2. Plastic Bottles and Containers

Commonly used plastics include HDPE, LDPE, PET, and polypropylene. Their impact on stability includes:

• Higher moisture vapor transmission rates (MVTR) than glass
• Potential interaction with lipophilic drugs
• Adsorption of preservatives or APIs
• Risk of leachables such as plasticizers or antioxidants

Plastics must meet compendial tests under USP and for water vapor permeability.

3. Aluminum Foil and Blister Packs

Aluminum foil is commonly used in blister packaging to provide light, moisture, and gas barriers. Two main types are:

• Alu-Alu: Best barrier, ideal for highly sensitive APIs
• Alu-PVC: Cost-effective but lower protection against moisture

Drug stability may differ significantly between these formats due to environmental exposure.

4. Rubber Stoppers and Closures

Used for vials, prefilled syringes, and IV bags, rubber closures can:

• Leach vulcanizing agents, accelerators, or fillers
• Cause extractables that migrate into the drug solution
• Interact with proteins in biologics, affecting stability

Closures must undergo GMP compliance testing and be evaluated under USP or protocols.

Influence of Packaging on Key Stability Factors

1. Moisture Sensitivity

Moisture can catalyze hydrolysis, cause degradation, or alter dosage form properties (e.g., tablet hardness). Packaging with high moisture barrier properties is essential for hygroscopic APIs:

• Use HDPE bottles with desiccants for oral solids
• Choose Alu-Alu blisters for extreme humidity zones
• Test WVTR during material qualification

ICH Climatic Zones III (hot dry) and IV (hot humid) require robust packaging validation.

2. Photostability

Drugs sensitive to light may undergo photodegradation, forming impurities or reducing potency. Protective strategies include:

• Amber-colored glass vials or bottles
• UV-blocking polymers in plastic containers
• Aluminum overwrap for blisters or flexible packaging

Photostability testing per ICH Q1B must reflect real packaging scenarios.

3. Oxygen Sensitivity

Oxidation reactions degrade many APIs and excipients. Packaging materials must reduce oxygen permeability:

• Use of oxygen scavengers within caps or closures
• Multilayered laminates with EVOH barrier in sachets or pouches
• Nitrogen flushing in headspace for vials and bottles

Assess oxygen ingress as part of container closure integrity testing (CCI).

4. Chemical Interaction and Adsorption

Some packaging materials may react with or adsorb drug substances, impacting potency or formulation consistency:

• Loss of preservatives in ophthalmic solutions due to plastic bottle wall absorption
• Binding of protein therapeutics to rubber or glass surfaces
• pH shift due to alkali leaching from untreated glass

Stability testing must be conducted using final packaging configuration to account for such risks.

Example: Impact of Blister Material on Drug Degradation

In a case study involving a highly moisture-sensitive tablet, two packaging options were evaluated: Alu-PVC and Alu-Alu. Real-time stability data showed that the drug degraded 12% over 12 months in Alu-PVC but remained stable in Alu-Alu. Based on these findings, the sponsor changed the primary packaging to Alu-Alu for all climatic zones.

Checklist: Factors for Packaging Material Selection

Conclusion

Packaging materials play a pivotal role in ensuring drug stability across the product lifecycle. The right choice of container-closure system—based on product sensitivity to moisture, oxygen, light, and chemical interactions—can prevent costly failures in stability studies and post-market complaints. Regulatory authorities expect the packaging used in commercial lots to match what is demonstrated during stability studies, making early and accurate material selection critical.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP , , , : Container and Material Standards
• EMA Guideline on Plastic Immediate Packaging Materials
• WHO Technical Report Series – Stability Testing of Pharmaceuticals
• FDA Guidance for Industry – Container Closure Systems for Packaging Human Drugs and Biologics

Packaging Materials Impact on Pharmaceutical Stability Testing

Introduction

Pharmaceutical packaging materials serve more than a containment role—they are active participants in preserving drug quality, safety, and efficacy. From shielding against moisture, oxygen, and light to ensuring physical protection, packaging materials must be carefully selected and validated to maintain product stability under ICH-recommended conditions. As Stability Studies simulate storage over time, the packaging’s performance becomes a critical determinant of shelf life and regulatory acceptance.

This article examines how packaging materials influence stability study outcomes. We explore different material types, their properties, compatibility with drug substances, regulatory expectations, and strategies for selecting and qualifying packaging materials in the pharmaceutical industry.

Types of Packaging Materials in Pharma

1. Plastics

• HDPE (High-Density Polyethylene): Common for solid oral dosages; good moisture barrier
• LDPE (Low-Density Polyethylene): Flexible; used in tubes and dropper bottles
• PET (Polyethylene Terephthalate): High clarity; used in oral liquids
• PP (Polypropylene): Resistant to heat and chemicals; used in injectable and ophthalmic packaging

2. Glass

• Type I: Borosilicate glass; inert and suitable for injectables
• Type II: Treated soda-lime glass; used for solutions
• Type III: Lower resistance; limited to non-aqueous solutions

3. Foils and Films

• PVC (Polyvinyl Chloride): Basic blister film; low barrier
• PVDC (Polyvinylidene Chloride): High moisture barrier for blister packs
• Aluminum Foil: Total barrier to light, oxygen, and moisture; used in cold-form blisters and sachets

4. Rubber and Elastomers

• Used for stoppers and gaskets; must be inert, non-reactive, and free of extractables

Critical Packaging Material Properties Affecting Stability

1. Moisture Permeability

Moisture ingress is one of the primary causes of degradation in hygroscopic drugs. Packaging must minimize water vapor transmission rate (WVTR), particularly for products stored in ICH Zone IVb (30°C/75% RH).

2. Oxygen Transmission Rate (OTR)

Oxygen-sensitive APIs can oxidize, impacting potency. Oxygen permeability testing is essential when using plastic bottles or films.

3. Light Transmission

Light exposure can degrade photosensitive products. ICH Q1B requires light-protective packaging for susceptible drugs, including amber containers or aluminum foil wraps.

4. Sorption and Leaching

• Sorption: API or excipients adsorb to packaging walls, lowering potency
• Leaching: Packaging components migrate into the product, risking toxicity

5. Thermal Stability

Packaging must withstand thermal cycling without degradation. This is especially relevant during accelerated testing (40°C/75% RH).

Regulatory Expectations for Packaging Materials in Stability

FDA

• 21 CFR 211.94: Containers must not be reactive, additive, or absorptive
• FDA Guidance on Container Closure Systems (1999): Describes testing and documentation expectations

ICH

• ICH Q1A(R2): Stability testing should use the same container-closure system as proposed for marketing
• ICH Q3B/Q3C: Impurities from degradation or leachables must be controlled

WHO

• TRS 961 Annex 9: Stability Studies must reflect real packaging conditions
• Focus on low- and middle-income countries with challenging climates

Material Testing and Validation

Extractables and Leachables Studies (E&L)

These studies identify and quantify potential leachables that can migrate from packaging into the drug product over time.

Testing Approaches

• Use exaggerated conditions (temperature, pH, solvents)
• Techniques: GC-MS, LC-MS, ICP-MS
• Performed for rubber stoppers, plastics, adhesives, inks

Permeation Testing

• Moisture Vapor Transmission Rate (MVTR): For blisters, sachets, bottles
• Oxygen Transmission Rate (OTR): For oxygen-sensitive APIs

Compatibility Studies

• Stress studies to test drug-packaging interactions
• pH stability, degradation profiling, color change monitoring

Packaging Material Qualification and SOPs

Qualification Steps

1. Supplier qualification and COA verification
2. Material ID testing (FTIR, DSC, TGA)
3. Initial extractables study
4. Stability study initiation with final packaging

Essential SOPs

• SOP for Packaging Material Evaluation
• SOP for Extractables and Leachables Testing
• SOP for Packaging Material Specification and Approval
• SOP for Container Closure System Validation

Common Packaging Material-Related Failures

1. Delamination of Foil Blisters

Occurs during high humidity or thermal cycling. Results in compromised barrier properties.

2. Container Crazing or Cracking

Plastic containers may degrade over time or react with solvents.

3. Color Change of Product

Indicates photodegradation due to insufficient light protection.

4. Leachables Above Threshold

Detected during long-term stability; may require a packaging switch or toxicology study.

Case Study: Moisture-Ingress Failure in PVC Blister

A fixed-dose combination tablet exhibited potency drop after 3 months of accelerated stability. Investigation showed high WVTR in standard PVC blisters. PVDC-coated film was substituted, restoring moisture barrier integrity. Retesting confirmed stability, and the new packaging was adopted for global launch.

Packaging Selection Strategy in Stability Programs

1. Start with High-Barrier Materials

Especially for new molecules with unknown sensitivity profiles.

2. Use Marketing-Equivalent Packaging for Registration Batches

Ensures that stability data aligns with what patients will receive.

3. Evaluate Environmental Sensitivity

• Moisture: Use foil or PVDC
• Oxygen: Consider glass or multilayer PET
• Light: Amber glass or UV-resistant plastics

Future Trends in Packaging Materials

• Smart polymers for active barrier response
• Sustainable and biodegradable films
• Digital moisture sensors integrated into packaging
• Automated integrity testing systems

Auditor Expectations

During a GMP Inspection

• Validated packaging specs and test reports
• Supplier change control documentation
• Risk assessment for material substitution
• Consistency between stability samples and marketed presentation

Conclusion

Packaging materials significantly influence pharmaceutical product stability, and their impact must be evaluated thoroughly through compatibility studies, regulatory alignment, and real-time stability testing. By integrating scientifically robust material selection strategies with GMP documentation, pharma companies can ensure product integrity and regulatory compliance across global markets. For SOP templates, test protocols, and packaging qualification checklists, visit Stability Studies.